NASDAQ:PACB - Pacific Biosciences Stock Price, Price Target & More

$2.53 -0.06 (-2.32 %)
(As of 04/23/2018 01:00 PM ET)
Previous Close$2.59
Today's Range$2.53 - $2.61
52-Week Range$2.02 - $5.70
Volume124,892 shs
Average Volume1.03 million shs
Market Capitalization$341.55 million
P/E Ratio-2.95
Dividend YieldN/A
Beta1.61

About Pacific Biosciences (NASDAQ:PACB)

Pacific Biosciences logoPacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.

Receive PACB News and Ratings via Email

Sign-up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNASDAQ:PACB
CUSIP69404D10
Phone650-521-8000

Debt

Debt-to-Equity Ratio0.16%
Current Ratio3.55%
Quick Ratio2.74%

Price-To-Earnings

Trailing P/E Ratio-2.95
Forward P/E Ratio-4.02
P/E GrowthN/A

Sales & Book Value

Annual Sales$93.47 million
Price / Sales3.57
Cash FlowN/A
Price / CashN/A
Book Value$0.74 per share
Price / Book3.42

Profitability

EPS (Most Recent Fiscal Year)($0.87)
Net Income$-92,180,000.00
Net Margins-98.63%
Return on Equity-98.98%
Return on Assets-59.92%

Miscellaneous

Employees456
Outstanding Shares131,870,000

How to Become a New Pot Stock Millionaire

Pacific Biosciences (NASDAQ:PACB) Frequently Asked Questions

What is Pacific Biosciences' stock symbol?

Pacific Biosciences trades on the NASDAQ under the ticker symbol "PACB."

How were Pacific Biosciences' earnings last quarter?

Pacific Biosciences (NASDAQ:PACB) released its earnings results on Thursday, February, 1st. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.02. The biotechnology company had revenue of $24.94 million for the quarter, compared to the consensus estimate of $21.89 million. Pacific Biosciences had a negative return on equity of 98.98% and a negative net margin of 98.63%. Pacific Biosciences's quarterly revenue was down 3.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.21) earnings per share. View Pacific Biosciences' Earnings History.

When is Pacific Biosciences' next earnings date?

Pacific Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, April, 24th 2018. View Earnings Estimates for Pacific Biosciences.

What price target have analysts set for PACB?

3 Wall Street analysts have issued 1 year target prices for Pacific Biosciences' stock. Their predictions range from $4.00 to $8.00. On average, they anticipate Pacific Biosciences' share price to reach $6.2667 in the next twelve months. View Analyst Ratings for Pacific Biosciences.

Are investors shorting Pacific Biosciences?

Pacific Biosciences saw a decline in short interest in March. As of March 29th, there was short interest totalling 10,469,372 shares, a decline of 19.4% from the March 15th total of 12,986,469 shares. Based on an average daily trading volume, of 1,118,752 shares, the short-interest ratio is currently 9.4 days. Currently, 9.0% of the company's stock are short sold.

Who are some of Pacific Biosciences' key competitors?

Who are Pacific Biosciences' key executives?

Pacific Biosciences' management team includes the folowing people:
  • Dr. Michael W. Hunkapiller, Exec. Chairman, CEO & Pres (Age 69)
  • Ms. Susan K. Barnes, Sr. VP & CFO (Age 64)
  • Mr. James Michael Phillips, Sr. VP of R&D (Age 67)
  • Ms. Kathy P. Ordoñez, Chief Commercial Officer, Exec. VP & Director (Age 67)
  • Dr. Stephen Turner Ph.D., Co-Founder, Chief Technology Officer and VP (Age 50)

Has Pacific Biosciences been receiving favorable news coverage?

News articles about PACB stock have trended somewhat positive recently, according to Accern. Accern identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pacific Biosciences earned a daily sentiment score of 0.09 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 46.32 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of Pacific Biosciences?

Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pacific Biosciences' stock price today?

One share of PACB stock can currently be purchased for approximately $2.53.

How big of a company is Pacific Biosciences?

Pacific Biosciences has a market capitalization of $341.55 million and generates $93.47 million in revenue each year. The biotechnology company earns $-92,180,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis. Pacific Biosciences employs 456 workers across the globe.

How can I contact Pacific Biosciences?

Pacific Biosciences' mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected]


MarketBeat Community Rating for Pacific Biosciences (PACB)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  184 (Vote Outperform)
Underperform Votes:  198 (Vote Underperform)
Total Votes:  382
MarketBeat's community ratings are surveys of what our community members think about Pacific Biosciences and other stocks. Vote "Outperform" if you believe PACB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PACB will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Pacific Biosciences (NASDAQ:PACB) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Pacific Biosciences in the last 12 months. Their average twelve-month price target is $6.2667, suggesting that the stock has a possible upside of 147.69%. The high price target for PACB is $8.00 and the low price target for PACB is $4.00. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.332.332.332.33
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.2667$6.2667$6.2667$8.9333
Price Target Upside: 147.69% upside55.50% upside55.50% upside70.16% upside

Pacific Biosciences (NASDAQ:PACB) Consensus Price Target History

Price Target History for Pacific Biosciences (NASDAQ:PACB)

Pacific Biosciences (NASDAQ:PACB) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/3/2017First AnalysisDowngradeOverweight -> Equal Weight$4.00N/AView Rating Details
9/28/2017CL KingDowngradeBuy -> Neutral$6.80HighView Rating Details
4/27/2017Cantor FitzgeraldSet Price TargetBuy$8.00MediumView Rating Details
11/3/2016JPMorgan ChaseReiterated RatingHold$12.00N/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

Pacific Biosciences (NASDAQ:PACB) Earnings History and Estimates Chart

Earnings by Quarter for Pacific Biosciences (NASDAQ:PACB)

Pacific Biosciences (NASDAQ:PACB) Earnings Estimates

2018 EPS Consensus Estimate: ($0.66)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.19)($0.19)($0.19)
Q2 20182($0.18)($0.17)($0.18)
Q3 20182($0.17)($0.16)($0.17)
Q4 20181($0.13)($0.13)($0.13)
Q1 20191($0.14)($0.14)($0.14)
Q2 20191($0.13)($0.13)($0.13)

Pacific Biosciences (NASDAQ PACB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/24/2018($0.18)N/AView Earnings Details
2/1/2018Q4 2017($0.1960)($0.18)$21.89 million$24.94 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.20)($0.19)$28.29 million$23.54 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.24)($0.26)$23.34 million$20.07 millionViewListenView Earnings Details
4/26/2017Q1 2017($0.23)($0.26)$23.80 million$24.90 millionViewN/AView Earnings Details
2/2/2017Q416($0.23)($0.21)$22.84 million$25.70 millionViewListenView Earnings Details
11/2/2016Q316($0.20)($0.19)$24.68 million$25.10 millionViewN/AView Earnings Details
8/4/2016Q2($0.22)($0.21)$20.19 million$20.70 millionViewN/AView Earnings Details
4/21/2016Q1($0.25)($0.23)$18.02 million$19.10 millionViewListenView Earnings Details
2/3/2016Q4($0.02)($0.02)$36.96 million$36.28 millionViewN/AView Earnings Details
10/22/2015Q3($0.27)$0.02$15.84 million$13.90 millionViewListenView Earnings Details
8/5/2015Q215($0.14)($0.16)$26.36 million$24.94 millionViewListenView Earnings Details
5/5/2015Q115($0.27)($0.27)$13.70 million$17.65 millionViewN/AView Earnings Details
2/3/2015Q414($0.26)($0.26)$14.90 million$16.90 millionViewListenView Earnings Details
10/23/2014Q214($0.16)($0.13)$17.20 million$20.60 millionViewListenView Earnings Details
7/24/2014Q114($0.15)($0.27)$11.39 million$11.40 millionViewN/AView Earnings Details
4/30/2014($0.28)($0.28)$10.17 million$11.64 millionViewN/AView Earnings Details
2/4/2014Q413($0.27)($0.26)$9.13 million$9.10 millionViewN/AView Earnings Details
10/22/2013Q313($0.30)($0.31)$7.08 million$7.40 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.35)($0.33)$6.09 million$6.04 millionViewN/AView Earnings Details
4/23/2013Q1 2013($0.37)($0.37)$4.28 million$5.60 millionViewN/AView Earnings Details
2/5/2013Q4 2012($0.37)($0.39)$4.38 million$5.90 millionViewN/AView Earnings Details
10/25/2012($0.45)($0.41)ViewN/AView Earnings Details
7/26/2012($0.46)($0.40)ViewN/AView Earnings Details
5/1/2012($0.47)($0.50)ViewN/AView Earnings Details
2/7/2012($0.50)($0.42)ViewN/AView Earnings Details
10/27/2011Q3 2011($0.60)($0.45)ViewN/AView Earnings Details
8/4/2011($0.63)($0.42)ViewN/AView Earnings Details
4/27/2011($0.67)($0.66)ViewN/AView Earnings Details
2/15/2011($0.91)($0.97)ViewN/AView Earnings Details
11/30/2010Q3 2010($39.70)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Pacific Biosciences (NASDAQ:PACB) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Pacific Biosciences (NASDAQ PACB) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.40%
Institutional Ownership Percentage: 58.93%
Insider Trading History for Pacific Biosciences (NASDAQ:PACB)
Institutional Ownership by Quarter for Pacific Biosciences (NASDAQ:PACB)

Pacific Biosciences (NASDAQ PACB) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/28/2016James Michael PhillipsSVPSell20,000$8.44$168,800.00201,449View SEC Filing  
7/29/2016James Michael PhillipsSVPSell20,000$8.45$169,000.00198,949View SEC Filing  
4/25/2016James Michael PhillipsSVPSell20,000$10.29$205,800.00201,449View SEC Filing  
3/2/2015Brian B DowVPBuy2,503$4.91$12,289.73View SEC Filing  
3/2/2015Kevin P CorcoranSVPBuy2,816$4.91$13,826.56View SEC Filing  
8/19/2014William W EricsonDirectorBuy39,299$5.14$201,996.86View SEC Filing  
8/18/2014William W EricsonDirectorBuy135,155$5.09$687,938.95View SEC Filing  
8/14/2014William W EricsonDirectorBuy77,822$5.00$389,110.00View SEC Filing  
8/13/2014William W EricsonDirectorBuy29,435$4.93$145,114.55View SEC Filing  
8/12/2014William W EricsonDirectorBuy123,423$4.89$603,538.47View SEC Filing  
12/12/2013Michael HunkapillerCEOBuy100,000$4.13$413,000.001,800,000View SEC Filing  
11/21/2013Michael HunkapillerCEOBuy200,000$3.61$722,000.001,700,000View SEC Filing  
12/3/2012Michael HunkapillerCEOBuy154,100$1.75$269,675.00View SEC Filing  
11/29/2012Michael HunkapillerCEOBuy242,200$1.68$406,896.00View SEC Filing  
11/26/2012Michael HunkapillerCEOBuy186,400$1.44$268,416.00View SEC Filing  
11/20/2012Michael HunkapillerCEOBuy155,000$1.27$196,850.00View SEC Filing  
11/16/2012Michael HunkapillerCEOBuy262,300$1.16$304,268.00View SEC Filing  
8/7/2012Michael HunkapillerCEOBuy400,000$1.75$700,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Pacific Biosciences (NASDAQ PACB) News Headlines

Source:
DateHeadline
Can Core Unit Drive Pacific Biosciences (PACB) Q1 Earnings?Can Core Unit Drive Pacific Biosciences' (PACB) Q1 Earnings?
www.msn.com - April 20 at 9:23 AM
Pacific Biosciences (PACB) Scheduled to Post Quarterly Earnings on TuesdayPacific Biosciences (PACB) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - April 17 at 2:49 AM
Pacific Biosciences (PACB) Receives Average Recommendation of "Hold" from AnalystsPacific Biosciences (PACB) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 16 at 1:44 AM
Pacific Biosciences (PACB) Stock Rating Lowered by BidaskClubPacific Biosciences (PACB) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 15 at 12:35 PM
Head to Head Contrast: Pacific Biosciences (PACB) versus Integra lifesciences (IART)Head to Head Contrast: Pacific Biosciences (PACB) versus Integra lifesciences (IART)
www.americanbankingnews.com - April 15 at 7:21 AM
Pacific Biosciences (PACB) Expected to Announce Quarterly Sales of $24.23 MillionPacific Biosciences (PACB) Expected to Announce Quarterly Sales of $24.23 Million
www.americanbankingnews.com - April 14 at 2:21 AM
BidaskClub Upgrades Pacific Biosciences (PACB) to "Hold"BidaskClub Upgrades Pacific Biosciences (PACB) to "Hold"
www.americanbankingnews.com - April 13 at 10:45 AM
Pacific Biosciences Gains as HudsonAlpha Picks Sequel SystemPacific Biosciences Gains as HudsonAlpha Picks Sequel System
finance.yahoo.com - April 13 at 9:33 AM
Short Interest in Pacific Biosciences (PACB) Decreases By 19.4%Short Interest in Pacific Biosciences (PACB) Decreases By 19.4%
www.americanbankingnews.com - April 13 at 3:23 AM
Pacific Biosciences (PACB) Expected to Post Earnings of -$0.19 Per SharePacific Biosciences (PACB) Expected to Post Earnings of -$0.19 Per Share
www.americanbankingnews.com - April 12 at 7:21 PM
Pacific Biosciences (PACB) Upgraded to "Sell" by BidaskClubPacific Biosciences (PACB) Upgraded to "Sell" by BidaskClub
www.americanbankingnews.com - April 12 at 6:14 PM
Pacific Biosciences (PACB) Downgraded to Hold at Zacks Investment ResearchPacific Biosciences (PACB) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 12 at 11:07 AM
Pacific Biosciences (PACB) Upgraded at Zacks Investment ResearchPacific Biosciences (PACB) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 11 at 9:52 AM
HudsonAlpha Using PacBio Sequencing for Childhood Developmental Disabilities ResearchHudsonAlpha Using PacBio Sequencing for Childhood Developmental Disabilities Research
finance.yahoo.com - April 11 at 9:51 AM
Pacific Biosciences: A Shovel Supplier To The Genomics MegatrendPacific Biosciences: A Shovel Supplier To The Genomics Megatrend
seekingalpha.com - April 10 at 4:40 PM
Genome Sequencing RoundupGenome Sequencing Roundup
seekingalpha.com - April 2 at 4:40 PM
Zacks: Brokerages Anticipate Pacific Biosciences of California (PACB) Will Post Quarterly Sales of $24.23 MillionZacks: Brokerages Anticipate Pacific Biosciences of California (PACB) Will Post Quarterly Sales of $24.23 Million
www.americanbankingnews.com - March 28 at 2:50 AM
Pacific Biosciences Announces Ten-Unit Sequel System Order for AnnoroadPacific Biosciences Announces Ten-Unit Sequel System Order for Annoroad
finance.yahoo.com - March 27 at 9:38 AM
Pacific Biosciences of California (PACB) Expected to Post Earnings of -$0.19 Per SharePacific Biosciences of California (PACB) Expected to Post Earnings of -$0.19 Per Share
www.americanbankingnews.com - March 26 at 9:12 PM
Health Care Sector Update for 03/23/2018: PACB, PGNX, PFE, GSK, VTVT - NasdaqHealth Care Sector Update for 03/23/2018: PACB, PGNX, PFE, GSK, VTVT - Nasdaq
www.nasdaq.com - March 23 at 4:40 PM
Pacific Biosciences Prevails in Patent Eligibility Ruling Against Oxford Nanopore - GlobeNewswire (press release)Pacific Biosciences Prevails in Patent Eligibility Ruling Against Oxford Nanopore - GlobeNewswire (press release)
globenewswire.com - March 22 at 4:41 PM
Pacific Biosciences Prevails in Patent Eligibility Ruling Against Oxford NanoporePacific Biosciences Prevails in Patent Eligibility Ruling Against Oxford Nanopore
finance.yahoo.com - March 22 at 4:41 PM
Pacific Biosciences of California (PACB) Receives Average Recommendation of "Hold" from AnalystsPacific Biosciences of California (PACB) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 22 at 1:52 AM
Study Demonstrates Potential for SMRT Sequencing to Improve the Safety of Gene Therapy ProtocolsStudy Demonstrates Potential for SMRT Sequencing to Improve the Safety of Gene Therapy Protocols
finance.yahoo.com - March 15 at 9:06 AM
Pacific Bio (PACB) Receives U.S. Patent for Concatemer SequencingPacific Bio (PACB) Receives U.S. Patent for Concatemer Sequencing
www.streetinsider.com - March 13 at 6:30 PM
Pacific Biosciences Announces Issuance of U.S. Patent for Concatemer SequencingPacific Biosciences Announces Issuance of U.S. Patent for Concatemer Sequencing
finance.yahoo.com - March 13 at 9:32 AM
Short Interest in Pacific Biosciences of California (PACB) Decreases By 10.8%Short Interest in Pacific Biosciences of California (PACB) Decreases By 10.8%
www.americanbankingnews.com - March 12 at 2:14 AM
Analyzing Cogentix Medical (CGNT) and Pacific Biosciences of California (PACB)Analyzing Cogentix Medical (CGNT) and Pacific Biosciences of California (PACB)
www.americanbankingnews.com - March 11 at 5:28 PM
$24.23 Million in Sales Expected for Pacific Biosciences of California (PACB) This Quarter$24.23 Million in Sales Expected for Pacific Biosciences of California (PACB) This Quarter
www.americanbankingnews.com - March 11 at 5:42 AM
-$0.19 Earnings Per Share Expected for Pacific Biosciences of California (PACB) This Quarter-$0.19 Earnings Per Share Expected for Pacific Biosciences of California (PACB) This Quarter
www.americanbankingnews.com - March 9 at 7:57 PM
Pacific Biosciences Enhances Performance and Affordability of Key Applications on the Sequel System - GlobeNewswire (press release)Pacific Biosciences Enhances Performance and Affordability of Key Applications on the Sequel System - GlobeNewswire (press release)
globenewswire.com - March 9 at 9:43 AM
Critical Review: Pacific Biosciences of California (PACB) vs. Reshape Lifesciences (RSLS)Critical Review: Pacific Biosciences of California (PACB) vs. Reshape Lifesciences (RSLS)
www.americanbankingnews.com - March 9 at 5:06 AM
Pacific Biosciences Unveils New Version of Sequel SoftwarePacific Biosciences Unveils New Version of Sequel Software
finance.yahoo.com - March 8 at 5:35 PM
Pacific Biosciences Enhances Performance and Affordability of Key Applications on the Sequel SystemPacific Biosciences Enhances Performance and Affordability of Key Applications on the Sequel System
finance.yahoo.com - March 7 at 9:22 AM
Pacific Biosciences (PACB) Down 15.6% Since Earnings Report: Can It Rebound?Pacific Biosciences (PACB) Down 15.6% Since Earnings Report: Can It Rebound?
finance.yahoo.com - March 5 at 9:24 AM
Maverick Capital Ltd. Acquires 619,150 Shares of Pacific Biosciences of California (PACB)Maverick Capital Ltd. Acquires 619,150 Shares of Pacific Biosciences of California (PACB)
www.americanbankingnews.com - March 1 at 4:25 PM
Pacific Biosciences of California (PACB) Short Interest UpdatePacific Biosciences of California (PACB) Short Interest Update
www.americanbankingnews.com - March 1 at 2:40 AM
Pacific Biosciences of California Inc (PACB) Files 10-K for the Fiscal Year Ended on December ...Pacific Biosciences of California Inc (PACB) Files 10-K for the Fiscal Year Ended on December ...
finance.yahoo.com - February 27 at 9:16 AM
Head to Head Contrast: Pacific Biosciences of California (PACB) versus Harvard Bioscience (HBIO)Head to Head Contrast: Pacific Biosciences of California (PACB) versus Harvard Bioscience (HBIO)
www.americanbankingnews.com - February 25 at 9:24 AM
Pacific Biosciences of California (PACB) Given Consensus Recommendation of "Hold" by AnalystsPacific Biosciences of California (PACB) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - February 25 at 1:24 AM
Are Options Traders Betting on a Big Move in Pacific Biosciences (PACB) Stock?Are Options Traders Betting on a Big Move in Pacific Biosciences (PACB) Stock?
www.zacks.com - February 21 at 9:16 AM
Biotech Stocks Research Reports Released on OvaScience, Pacific Biosciences of California, Neuralstem, and Pieris PharmaBiotech Stocks' Research Reports Released on OvaScience, Pacific Biosciences of California, Neuralstem, and Pieris Pharma
www.bizjournals.com - February 14 at 9:18 AM
Pacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common StockPacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - February 13 at 9:24 AM
Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common StockPacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock
finance.yahoo.com - February 12 at 4:22 PM
SMRT Sequencing of Human Genomes to be Showcased at AGBT ConferenceSMRT Sequencing of Human Genomes to be Showcased at AGBT Conference
finance.yahoo.com - February 12 at 9:12 AM
Q1 2018 EPS Estimates for Pacific Biosciences of California (PACB) Reduced by AnalystQ1 2018 EPS Estimates for Pacific Biosciences of California (PACB) Reduced by Analyst
www.americanbankingnews.com - February 9 at 8:52 AM
Pacific Biosciences (PACB) Q4 Loss Narrows, Consumables Up - NasdaqPacific Biosciences (PACB) Q4 Loss Narrows, Consumables Up - Nasdaq
www.nasdaq.com - February 4 at 4:35 PM
Luminex (LMNX) & Pacific Biosciences of California (PACB) Critical SurveyLuminex (LMNX) & Pacific Biosciences of California (PACB) Critical Survey
www.americanbankingnews.com - February 3 at 1:28 PM
Whats Behind Pacific Biosciences of Californias Sinking Fourth-Quarter SalesWhat's Behind Pacific Biosciences of California's Sinking Fourth-Quarter Sales
www.fool.com - February 2 at 9:19 AM
What's Behind Pacific Biosciences of California's Sinking Fourth-Quarter SalesWhat's Behind Pacific Biosciences of California's Sinking Fourth-Quarter Sales
finance.yahoo.com - February 2 at 9:19 AM

SEC Filings

Pacific Biosciences (NASDAQ:PACB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Pacific Biosciences (NASDAQ:PACB) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Pacific Biosciences (NASDAQ PACB) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.